FDA proposes new rules to modernize drug manufacturing registration and enhance supply chain oversight

The U.S. FDA has proposed new regulations aimed at streamlining the registration process for advanced distributed drug manufacturing facilities. This initiative seeks to improve the resilience of the domestic pharmaceutical supply chain and increase transparency regarding foreign drug sources. The proposed rule intends to ensure consistent access to safe and high-quality medications for American consumers.